{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:12:22Z","timestamp":1777867942185,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2008,2,8]],"date-time":"2008-02-08T00:00:00Z","timestamp":1202428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2008,2,8]],"date-time":"2008-02-08T00:00:00Z","timestamp":1202428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Neurol"],"abstract":"<jats:p>The efficacy and safety of sumatriptan, a selective 5-HT&lt;sub&gt;1&lt;\/sub&gt; like receptor agonist, were studied in a randomized, double-blind, placebo-controlled, parallel-group, multicentre, multinational clinical trial of 235 patients suffering a moderate to severe migraine attack. Patients were randomized to treat a single migraine attack at home with 6 mg sumatriptan or placebo using an auto-injector. If the migraine had not improved at 1 h, patients had the option of taking a second identical injection. The primary measure of treatment efficacy was based on a comparison of the number of patients in the two treatment groups who had a reduction in headache severity from severe or moderate to mild or none at 1 and 2 h. At 1 h, 77% of patients treating with 6 mg sumatriptan compared to 26% treating with placebo (p &lt; 0.001) had mild headache or none. At 2 h, the response rates for all patients had risen to 83 and 30%, respectively. Of those patients requiring a second dose at 1 h, improvement to mild or no headache at 2 h was achieved in 61 % of patients receiving sumatriptan compared to 15 % of those receiving placebo. Other migraine symptoms were more effectively treated by sumatriptan and patients were able to return to work or normal activities earlier. Migraine recurrence within 48 h was a feature of 46% of attacks treated by patients with either treatment. Adverse events were more frequent using sumatriptan but were minor and transient. It is concluded that 6 mg sumatriptan, self-administered using an auto-injector, is an effective and well-tolerated acute treatment for migraine, with an efficacy rate similar to that seen when sumatriptan is administered subcutaneously by a physician.<\/jats:p>","DOI":"10.1159\/000116760","type":"journal-article","created":{"date-parts":[[2008,2,8]],"date-time":"2008-02-08T05:59:29Z","timestamp":1202450369000},"page":"323-331","source":"Crossref","is-referenced-by-count":64,"title":["Self-Treatment of Acute Migraine with Subcutaneous Sumatriptan Using an Auto-Injector Device"],"prefix":"10.1159","member":"127","published-online":{"date-parts":[[2008,2,8]]},"container-title":["European Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/116760","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000116760","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T11:13:12Z","timestamp":1777547592000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000116760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,8]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000116760","archive":["Portico"],"relation":{},"ISSN":["0014-3022","1421-9913"],"issn-type":[{"value":"0014-3022","type":"print"},{"value":"1421-9913","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,8]]}}}